1. (N)-Methanocarba 2,N<SUP>6</SUP>-Disubstituted Adenine Nucleosides as Highly Potent and Selective A<INF>3</INF> Adenosine Receptor Agonists
- Author
-
Tchilibon, S., Joshi, B. V., Kim, S.-K., Duong, H. T., Gao, Z.-G., and Jacobson, K. A.
- Abstract
A series of ring-constrained (N)-methanocarba-5-uronamide 2,N6-disubstituted adenine nucleosides have been synthesized via Mitsunobu condensation of the nucleobase precursor with a pseudosugar ring containing a 5-ester functionality. Following appropriate functionalization of the adenine ring, the ester group was converted to the 5-N-methylamide. The compounds, mainly 2-chloro-substituted derivatives, were tested in both binding and functional assays at human adenosine receptors (ARs), and many were found to be highly potent and selective A
3 AR agonists. Selected compounds were compared in binding to the rat A3 AR to assess their viability for testing in rat disease models. The N6-(3-chlorobenzyl) and N6-(3-bromobenzyl) analogues displayed Ki values at the human A3 AR of 0.29 and 0.38 nM, respectively. Other subnanomolar affinities were observed for the following N6 derivatives: 2,5-dichlorobenzyl, 5-iodo-2-methoxybenzyl, trans-2-phenyl-1-cyclopropyl, and 2,2-diphenylethyl. Selectivity for the human A3 AR in comparison to the A1 AR was the following (fold): the N6-(2,2-diphenylethyl) analogue34 (1900), the N6-(2,5-dimethoxybenzyl) analogue26 (1200), the N6-(2,5-dichlorobenzyl) and N6-(2-phenyl-1-cyclopropyl) analogues20 and33 (1000), and the N6-(3-substituted benzyl) analogues17 ,18 ,28 , and29 (700−900). Typically, even greater selectivity ratios were obtained in comparison with the A2A and A2B ARs. The (N)-methanocarba-5-uronamide analogues were full agonists at the A3 AR, as indicated by the inhibition of forskolin-stimluated adenylate cyclase at a concentration of 10 μM. The N6-(2,2-diphenylethyl) derivative was an A3 AR agonist in the (N)-methanocarba-5-uronamide series, although it was an antagonist in the ribose series. Thus, many of the previously known groups that enhance A3 AR affinity in the 9-riboside series, including those that reduce intrinsic efficacy, may be adapted to the (N)-methanocarba nucleoside series of full agonists.- Published
- 2005